Kazuki Ikai

Kazuki Ikai

Auto-generated profile, based on publicly available information

Kazuki Ikai

Department of Oral‐facial Disorders Osaka University Graduate School of Dentistry Suita Japan

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 August 2020 in FEBS Letters
Verified
Journal Article
Open access
PDF file
KIKazuki Ikai
Kazuki Ikai
MSManabu Sakai
Manabu Sakai
HOHitomi Ono-Minagi
Hitomi Ono-Minagi
NGNao Gojo
Nao Gojo
TSTakayoshi Sakai
Takayoshi Sakai
The transcription factor p63, a component of the p53 family, has important functions in development, homeostasis, and regeneration of epithelial tissues. However, the role of p63 in the regeneration of exocrine glands, including the salivary glands (SGs), has not been fully investigated. We investigated p63 expression in SG regeneration induced by duct ligation and irradiation. The expression of ΔNp63, a p63 isoform, increased and was colocalized with keratin 5 positive cells were myoepithelial cells. Furthermore, ΔNp63 expression was regulated by FGF7 stimulation via p38 MAPK phosphorylation and affected SG morphogenesis. These results suggest that ΔNp63 is essential for SG regeneration and may be a new target for regenerative treatment.

27 April 2018 in SLEEP
Verified
Journal Article
Open access
PDF file
KOKentaro OKUNO
Kentaro OKUNO
HOH Minagi Ono
H Minagi Ono
KIK Ikai
K Ikai
EAE Matsumura Ai
E Matsumura Ai
ETE Takai
E Takai
TSTakayoshi Sakai
Takayoshi Sakai
We performed a prospective study to evaluate the efficacy of nasal airway stent (Nastent) treatment, a nasopharyngeal stent that maintains the patency of the nasal airway to the nasopharynx and oropharynx during sleep, and examined predictors for Nastent treatment outcomes in patients with obstructive sleep apnea (OSA). Thirty patients were enrolled in this study. Cephalometric radiographs were obtained to analyze the craniofacial morphology at baseline. Before and after Nastent treatment, we evaluated OSA using a portable sleep study and Epworth Sleepiness Scale (ESS). Twenty-nine subjects completed this study. There were significant decreases in the apnea hypopnea index (AHI) (22.4 ± 14.1 to 15.7 ± 10.4, p<0.01), CT<90% (2.3 ± 3.9 to 0.4 ± 0.7, p<0.05), and ESS (12.1 ± 4.3 to 6.7 ± 4.0, p<0.01), and a significant increase in the lowest SpO2 (81.9 ± 7.5 to 86.6 ± 4.8, p50% compared with baseline AHI. We evaluated the ratio of inferior airway space and middle airway space (IAS/MAS) on cephalograms as the index of the narrowest airway site. The IAS/MAS was significantly higher in responders than in non-responders (1.4 ± 0.9 vs. 0.9 ± 0.4, p<0.01) and predicted treatment responders with high accuracy (sensitivity: 90.9%, specificity: 88.9%, when IAS/MAS was set at 1.10). The Nastent device improved OSA, and cephalograms predicted treatment response with good sensitivity and specificity. Support (If Any):